We report that the therapeutic combination of DHODH inhibition and the standard-of-care chemotherapeutic temozolomide has curative potential in a transgenic neuroblastoma mouse model and may be a promising candidate for the treatment of high-risk neuroblastoma. This evidence concerns the gene DHODH and neuroblastoma.